Skip to main content

ÍS
EN

Forsíða

Forsíða

Sæmundur Rögnvaldsson - Research Specialist

Sæmundur Rögnvaldsson

–

Heilbrigðisvísindasvið

Sæmundur Rögnvaldsson

Research Specialist

Email
srognvald [at] hi.is

Unit
Research Faculty of Medicine

Published works

2024

Association Between Autoimmune Diseases and Monoclonal Gammopathy of Undetermined SignificanceAnnals of Internal Medicine
Development of a Multivariable Model to Predict the Need for Bone Marrow Sampling in Persons With Monoclonal Gammopathy of Undetermined SignificanceAnnals of Internal Medicine

2023

Validity of chronic disease diagnoses in Icelandic healthcare registriesScandinavian Journal of Public Health
The force awakens, but questions remain: The future of MGUSBritish Journal of Haematology
Correction: Iceland screens, treats, or prevents multiple myeloma (iStopMM): a population-based screening study for monoclonal gammopathy of undetermined significance and randomized controlled trial of follow-up strategiesBlood Cancer Journal
Determining hemodilution in diagnostic bone marrow aspirated samples in plasma cell disorders by next-generation flow cytometry: Proposal for a bone marrow quality indexBlood Cancer Journal

2022

Defining new reference intervals for serum free light chains in individuals with chronic kidney disease: Results of the iStopMM studyBlood Cancer Journal

2021

Monoclonal gammopathy of undetermined significance and COVID-19: a population-based cohort studyBlood Cancer Journal
Untangling fracture risk in monoclonal gammopathy of undetermined significance: A population‐based cohort studyEuropean Journal of Haematology
Iceland screens, treats, or prevents multiple myeloma (iStopMM): a population-based screening study for monoclonal gammopathy of undetermined significance and randomized controlled trial of follow-up strategiesBlood Cancer Journal

Keywords for Specialisation:

Multiple myeloma

Hematological cancers

Internal medicine